UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

Annals of oncology, 2015-02, Vol.26 (2), p.368-374

2015

Volltextzugriff (PDF)

Fusarium biocontrol: antagonism and mycotoxin elimination by lactic acid bacteria

Frontiers in microbiology, 2024-01, Vol.14, p.1260166-1260166

2024

Volltextzugriff (PDF)

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

European journal of cancer (1990), 2016-01, Vol.53, p.75-83

2016

Volltextzugriff (PDF)

Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group

Annals of oncology, 2019-03, Vol.30 (3), p.490-491

2019

Volltextzugriff (PDF)

DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (R/R LBCL)

Hematological oncology, 2023-06, Vol.41 (S2), p.85-86

2023

Volltextzugriff (PDF)

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

Blood cancer journal (New York), 2016-01, Vol.6 (1), p.e378-e378

2016

Volltextzugriff (PDF)

Biosorption of Ni(II) Using Seeds of Mirabilis Jalapa

Bioremediation and Green Technologies, p.55-66

Volltextzugriff (PDF)

Short-Term Disability (STD) Associated with Skeletal Related Events (SRES) in Commercially Insured Patients with Bone Metastases (BM) Secondary to Solid Tumors

Value in health, 2013-11, Vol.16 (7), p.A417-A417

2013

Volltextzugriff (PDF)

Burden and Timing of First and Subsequent Skeletal Related Events (SRES) in United States Elderly Men with Metastatic Prostate Cancer (MPC)

Value in health, 2014-05, Vol.17 (3), p.A72-A72

2014

Volltextzugriff (PDF)

PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE‐013 TRIAL

Hematological oncology, 2017-06, Vol.35 (S2), p.189-190

2017

Volltextzugriff (PDF)

PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE‐087 STUDY

Hematological oncology, 2017-06, Vol.35 (S2), p.136-137

2017

Volltextzugriff (PDF)

Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

Hematological oncology, 2017-06, Vol.35 (S2), p.62-63

2017

Volltextzugriff (PDF)

Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future

Clinical lymphoma, myeloma and leukemia, 2010-08, Vol.10 (4), p.248-257

2010

Volltextzugriff (PDF)

A trial-based EUROQOL EQ-5D health utility analysis in patients with classical Hodgkin's lymphoma

Annals of oncology, 2017-09, Vol.28, p.v397-v397

2017

Volltextzugriff (PDF)

1. Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios

Value in health, 2018-05, Vol.21, p.S223

2018

Volltextzugriff (PDF)

PRM79 - 1. Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios

Value in health, 2018-05, Vol.21, p.S223-S223

2018

Volltextzugriff (PDF)

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases

Supportive care in cancer, 2016-03, Vol.24 (3), p.1327-1337

2016

Volltextzugriff (PDF)

High resolution esophageal manometry—The switch from “intuitive” visual interpretation to Chicago classification

Indian journal of gastroenterology, 2014-03, Vol.33 (2), p.157-160

2014

Volltextzugriff (PDF)

Antioxidants and lipid peroxidation status in diabetic patients with and without complications

Archives of Iranian medicine, 2009-03, Vol.12 (2), p.121

2009

Volltextzugriff (PDF)

Developmental Vasculotoxicity Associated with Inhibition of Semicarbazide-Sensitive Amine Oxidase

Toxicology and applied pharmacology, 1999-03, Vol.155 (3), p.237-244

1999

Volltextzugriff (PDF)

The dilemma of diagnosing the cause of hypernatraemia: drinking habits vs diabetes insipidus

Nephrology, dialysis, transplantation, 2004-12, Vol.19 (12), p.3165-3167

2004

Volltextzugriff (PDF)

A Study of Bacterial Isolates from Impetigo and their Resistance Pattern to Mupirocin

International journal of current microbiology and applied sciences, 2019-09, Vol.8 (9), p.570-576

2019

Volltextzugriff (PDF)

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study

Annals of oncology, 2016-11, Vol.27, p.viii17-viii17

2016

Volltextzugriff (PDF)

Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors

Expert review of clinical pharmacology, 2012-07, Vol.5 (4), p.359-371

2012

Volltextzugriff (PDF)

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

Hematological oncology, 2023-06, Vol.41 Suppl 2, p.85

2023

Volltextzugriff (PDF)

1 – 25 von 479

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(394)
Mit Volltextzugriff
(381)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

Fusarium biocontrol: antagonism and mycotoxin elimination by lactic acid bacteria

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group

DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (R/R LBCL)

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

Biosorption of Ni(II) Using Seeds of Mirabilis Jalapa

Short-Term Disability (STD) Associated with Skeletal Related Events (SRES) in Commercially Insured Patients with Bone Metastases (BM) Secondary to Solid Tumors

Burden and Timing of First and Subsequent Skeletal Related Events (SRES) in United States Elderly Men with Metastatic Prostate Cancer (MPC)

PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE‐013 TRIAL

PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE‐087 STUDY

Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future

A trial-based EUROQOL EQ-5D health utility analysis in patients with classical Hodgkin's lymphoma

1. Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios

PRM79 - 1. Indirect Treatment Comparison of Pembrolizumab Versus Standard-of-Care for Relapsed and Refractory Classical Hodgkin’s Lymphoma Using Time-Varying Hazard Ratios

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases

High resolution esophageal manometry—The switch from “intuitive” visual interpretation to Chicago classification

Antioxidants and lipid peroxidation status in diabetic patients with and without complications

Developmental Vasculotoxicity Associated with Inhibition of Semicarbazide-Sensitive Amine Oxidase

The dilemma of diagnosing the cause of hypernatraemia: drinking habits vs diabetes insipidus

A Study of Bacterial Isolates from Impetigo and their Resistance Pattern to Mupirocin

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study

Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

Suchergebnisse filtern